title: Both coding exons of the c-myc gene contribute to its posttranscriptional regulation in the quiescent liver and regenerating liver and after protein synthesis inhibition.
abstract: In vivo, the steady-state level of c-myc mRNA is mainly controlled by posttranscriptional mechanisms. Using a panel of transgenic mice in which various versions of the human c-myc proto-oncogene were under the control of major histocompatibility complex H-2Kb class I regulatory sequences, we have shown that the 5' and the 3' noncoding sequences are dispensable for obtaining a regulated expression of the transgene in adult quiescent tissues, at the start of liver regeneration, and after inhibition of protein synthesis. These results indicated that the coding sequences were sufficient to ensure a regulated c-myc expression. In the present study, we have pursued this analysis with transgenes containing one or the other of the two c-myc coding exons either alone or in association with the c-myc 3' untranslated region. We demonstrate that each of the exons contains determinants which control c-myc mRNA expression. Moreover, we show that in the liver, c-myc exon 2 sequences are able to down-regulate an otherwise stable H-2K mRNA when embedded within it and to induce its transient accumulation after cycloheximide treatment and soon after liver ablation. Finally, the use of transgenes with different coding capacities has allowed us to postulate that the primary mRNA sequence itself and not c-Myc peptides is an important component of c-myc posttranscriptional regulation.
authors.affiliation: Department of Immunology, Institut Pasteur, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Lavenu
authors.forename: S
authors.initials: S
authors.lastname: Pistoi
authors.forename: S
authors.initials: S
authors.lastname: Pournin
authors.forename: C
authors.initials: C
authors.lastname: Babinet
authors.forename: D
authors.initials: D
authors.lastname: Morello
mesh_terms: D000818:Animals; D001483:Base Sequence; D003513:Cycloheximide / Q000494:pharmacology; D005091:Exons / Q000235:genetics*; D018507:Gene Expression Regulation, Developmental; D016259:Genes, myc / Q000235:genetics*; D006183:H-2 Antigens / Q000096:biosynthesis / Q000235:genetics; D006498:Hepatectomy; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000254:growth & development* / Q000378:metabolism; D008115:Liver Regeneration / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D000090063:Proto-Oncogene Mas; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D012323:RNA Processing, Post-Transcriptional; D012333:RNA, Messenger / Q000378:metabolism
chemical_list: D006183:H-2 Antigens; C032876:H-2Kb protein, mouse; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D003513:Cycloheximide